Search

Meet our new AseBio member, Intusomics Analytics. We spoke with Daniel Arenas González, Founder & CEO.

New Drug Discovery and Biomaterials, two of the event's three main pillars. The gathering offers debates, workshops, and 1-to-1 meetings with investors and corporations.

This September, Klinea will be taking part in Farmaforum and BIOSPAIN 2026, two of the leading events in the pharmaceutical and biotechnology industry in Spain.

iPremom, a molecular diagnostics company dedicated to the earliest prediction of pregnancy complications, has raised €15m in seed funding led by Amadeus Capital Partners, co-led by Asabys (Sabadell

BCN HEALTH participated in the European Association for the Study of the Liver (EASL) International Liver Congress (ILC 2026), which took place in May in Barcelona, Spain. Two new communications were

Atlas Molecular Pharma, a Basque biotech developing pharmacological chaperone therapies for rare diseases, announces that the first three patients enrolled in its Phase 2 clinical trial of ATL-001 are

This pioneering project in Spain aims to support the diagnosis of haematological diseases through AI applied to bone marrow analysis. The initiative reduces analysis times by up to 80% and minimizes

Batea Oncology and dsm-firmenich are building on a longstanding collaboration dedicated to advancing GlioHook®, an innovative mechanomedicine-based medical device being developed for glioblastoma

The company has achieved a 4.18% reduction in emissions in the 2023–2025 three-year period compared with 2022–2024, for Scope 1+2.

With an extensive professional, institutional and academic background, Sempere joins the consultancy to drive its strategic growth plan and strengthen its presence in key markets.

The company will have a stand at Photonics 2026, where it will present its new Node I centre, featuring office space, laboratories and specialised infrastructure for R&D and deep-tech companies.

The Autonomous University of Madrid (UAM) will host the first edition of BSD Data Days on 15 October, an event promoted by BioSmartData (BSD) in collaboration with UAM and the Autonomous University of

Iadademstat is under clinical development in acute myeloid leukemia (AML), including in combination with gilteritinib in the Phase Ib FRIDA trial in patients with FLT3-mutated relapsed/refractory (R/R

From clinical data to drug discovery: Madrid-based biotech Neural Omega will make its international debut at BioSpain 2026 (Bilbao, September 29–October 1), presenting a technology pipeline that turns

Almirall and Certest Biotec, S.L., through its pharmaceutical division, Certest Pharma, have entered into a strategic research collaboration and licensing agreement to jointly discover and clinically